A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2019
At a glance
- Drugs DNL-201 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Denali Therapeutics Inc
- 10 Dec 2018 According to a Denali Therapeutics Inc media release, dosing has been initiated in this trial. Data readout from this study is expected during Q4 2019.
- 08 Nov 2018 According to a Denali Therapeutics Inc media release, first patient expected to be dosed in late 2018.
- 08 Nov 2018 Status changed from not yet recruiting to recruiting, according to a Denali Therapeutics Inc media release.